Merus to Present at the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Merus N.V. (Nasdaq: MRUS) announced that its CEO, Bill Lundberg, will present at the H.C. Wainwright Global Investment Conference. This presentation will occur on May 24, 2022, with a live webcast available at 7:00 a.m. ET on the company's Investors page. An archived version will be accessible for a limited time following the event.

Merus focuses on developing innovative full-length multispecific antibodies, including its proprietary Biclonics® and Triclonics® therapies, which have demonstrated promising features in clinical studies.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics^® and Triclonics^®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at the H.C. Wainwright Global Investment Conference.

The webcast of the presentation will be available on-demand starting on May 24, 2022 at 7:00 a.m. ET and will be contemporaneously available on the Investors page of the Company’s website. The archived presentation will also be available there for a limited time after the event.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics^®. Multiclonics^® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.

FAQ

When will Merus present at the H.C. Wainwright Global Investment Conference?

Merus N.V. will present at the H.C. Wainwright Global Investment Conference on May 24, 2022.

What time will the Merus presentation start?

The presentation by Merus N.V. will start at 7:00 a.m. ET on May 24, 2022.

Where can I watch the Merus presentation?

The Merus presentation will be available via a live webcast on the company's Investors page.

Will the Merus presentation be available after the event?

Yes, an archived version of the Merus presentation will be available for a limited time after the event.

What does Merus focus on developing?

Merus N.V. focuses on developing innovative full-length multispecific antibodies, specifically Biclonics® and Triclonics®.